报价延迟最少15分钟:2025/09/04 05:14 EDT
盘前时段
|
||||
|
22.7 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.96
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.59/-3.10
|
|
企业价值
1.50B
|
| 资产负债 |
|
每股账面净值
7.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/04 05:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
